BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1593 related articles for article (PubMed ID: 26096609)

  • 1. SCD-HeFT: Use of R-R interval statistics for long-term risk stratification for arrhythmic sudden cardiac death.
    Au-Yeung WT; Reinhall PG; Poole JE; Anderson J; Johnson G; Fletcher RD; Moore HJ; Mark DB; Lee KL; Bardy GH
    Heart Rhythm; 2015 Oct; 12(10):2058-66. PubMed ID: 26096609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of the 6-min walk distance to identify variations in treatment benefits from implantable cardioverter-defibrillator and amiodarone: results from the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial).
    Fishbein DP; Hellkamp AS; Mark DB; Walsh MN; Poole JE; Anderson J; Johnson G; Lee KL; Bardy GH;
    J Am Coll Cardiol; 2014 Jun; 63(23):2560-2568. PubMed ID: 24727258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Syncope predicts the outcome of cardiomyopathy patients: analysis of the SCD-HeFT study.
    Olshansky B; Poole JE; Johnson G; Anderson J; Hellkamp AS; Packer D; Mark DB; Lee KL; Bardy GH;
    J Am Coll Cardiol; 2008 Apr; 51(13):1277-82. PubMed ID: 18371559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II.
    Klein H; Auricchio A; Reek S; Geller C
    Am J Cardiol; 1999 Mar; 83(5B):91D-97D. PubMed ID: 10089848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary prevention with defibrillator therapy in women: results from the Sudden Cardiac Death in Heart Failure Trial.
    Russo AM; Poole JE; Mark DB; Anderson J; Hellkamp AS; Lee KL; Johnson GW; Domanski M; Bardy GH
    J Cardiovasc Electrophysiol; 2008 Jul; 19(7):720-4. PubMed ID: 18373605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implantable cardioverter defibrillators. Prophylactic use: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2005; 5(14):1-74. PubMed ID: 23074465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid-rate nonsustained ventricular tachycardia found on implantable cardioverter-defibrillator interrogation: relationship to outcomes in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial).
    Chen J; Johnson G; Hellkamp AS; Anderson J; Mark DB; Lee KL; Bardy GH; Poole JE
    J Am Coll Cardiol; 2013 May; 61(21):2161-8. PubMed ID: 23541974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Where patients with mild to moderate heart failure die: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).
    Olshansky B; Wood F; Hellkamp AS; Poole JE; Anderson J; Johnson GW; Boineau R; Domanski MJ; Mark DB; Lee KL; Bardy GH;
    Am Heart J; 2007 Jun; 153(6):1089-94. PubMed ID: 17540216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).
    Freudenberger RS; Hellkamp AS; Halperin JL; Poole J; Anderson J; Johnson G; Mark DB; Lee KL; Bardy GH;
    Circulation; 2007 May; 115(20):2637-41. PubMed ID: 17485579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial.
    Packer DL; Prutkin JM; Hellkamp AS; Mitchell LB; Bernstein RC; Wood F; Boehmer JP; Carlson MD; Frantz RP; McNulty SE; Rogers JG; Anderson J; Johnson GW; Walsh MN; Poole JE; Mark DB; Lee KL; Bardy GH
    Circulation; 2009 Dec; 120(22):2170-6. PubMed ID: 19917887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-benefit analysis of primary prevention of sudden cardiac death with an implantable cardioverter defibrillator versus amiodarone in Canada.
    Deniz HB; Ward A; Jaime Caro J; Alvarez P; Sadri H
    Curr Med Res Opin; 2009 Mar; 25(3):617-26. PubMed ID: 19232036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Outcomes of Implantable Cardioverter-Defibrillator Therapy in the SCD-HeFT.
    Poole JE; Olshansky B; Mark DB; Anderson J; Johnson G; Hellkamp AS; Davidson-Ray L; Fishbein DP; Boineau RE; Anstrom KJ; Reinhall PG; Packer DL; Lee KL; Bardy GH;
    J Am Coll Cardiol; 2020 Jul; 76(4):405-415. PubMed ID: 32703511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implantable Cardioverter-Defibrillator Placement for Primary Prevention in 2,346 Patients: Predictors of One-Year Survival.
    Merchant FM; Desai Y; Addish MA; Kelly K; Casey M; Goyal A; Leon AR; El-Chami MF
    Tex Heart Inst J; 2018 Aug; 45(4):221-225. PubMed ID: 30374229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel method to predict the proportional risk of sudden cardiac death in heart failure: Derivation of the Seattle Proportional Risk Model.
    Shadman R; Poole JE; Dardas TF; Mozaffarian D; Cleland JG; Swedberg K; Maggioni AP; Anand IS; Carson PE; Miller AB; Levy WC
    Heart Rhythm; 2015 Oct; 12(10):2069-77. PubMed ID: 26142301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autonomic markers and cardiovascular and arrhythmic events in heart failure patients: still a place in prognostication? Data from the GISSI-HF trial.
    La Rovere MT; Pinna GD; Maestri R; Barlera S; Bernardinangeli M; Veniani M; Nicolosi GL; Marchioli R; Tavazzi L;
    Eur J Heart Fail; 2012 Dec; 14(12):1410-9. PubMed ID: 22851700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Midlands Trial of Empirical Amiodarone versus Electrophysiology-guided Interventions and Implantable Cardioverter-defibrillators (MAVERIC): a multi-centre prospective randomised clinical trial on the secondary prevention of sudden cardiac death.
    Lau EW; Griffith MJ; Pathmanathan RK; Ng GA; Clune MM; Cooper J; Marshall HJ; Forsey PR; Stafford PJ; Gray RG; Skehan JD; Garratt CJ
    Europace; 2004 Jul; 6(4):257-66. PubMed ID: 15172648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arrhythmia risk stratification with regard to prophylactic implantable defibrillator therapy in patients with dilated cardiomyopathy. Results of MACAS, DEFINITE, and SCD-HeFT.
    Grimm W; Alter P; Maisch B
    Herz; 2004 May; 29(3):348-52. PubMed ID: 15167963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No benefit of a dual coil over a single coil ICD lead: evidence from the Sudden Cardiac Death in Heart Failure Trial.
    Aoukar PS; Poole JE; Johnson GW; Anderson J; Hellkamp AS; Mark DB; Lee KL; Bardy GH
    Heart Rhythm; 2013 Jul; 10(7):970-6. PubMed ID: 23562699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 80.